@article { author = {Mehdipour, Fereshteh and Malekzadeh, Mahyar and Talei, Abdolrasoul and Ghaderi, Abbas}, title = {Decreased Serum Level of Interleukin-19 in Iranian Patients with Breast Cancer}, journal = {Middle East Journal of Cancer}, volume = {6}, number = {4}, pages = {203-209}, year = {2015}, publisher = {Shiraz University of Medical Sciences}, issn = {2008-6709}, eissn = {2008-6687}, doi = {}, abstract = {Background: Interleukin-19, a member of the interleukin-10 family of cytokines,contributes to breast cancer pathogenesis. High interleukin-19 expression in breasttumor tissues is associated with poor clinical outcome. This study aimed to assessthe changes in serum level of interleukin-19 in breast cancer patients in comparisonwith normal women and its association with the clinicopathological parameters ofthis disease.Methods: Enzyme-linked  immunosorbent  assay was used  to  analyze  serumlevels of interleukin-19 in 116 women with breast cancer before chemotherapy orradiotherapy, and in 60 healthy age-matched women without any acute or chronicdiseases or family history of cancer.Results: There were significantly lower serum interleukin-19 levels in breast cancerpatients  (median:  27.3  pg/ml;  range:  10.5-2443.6 pg/ml)  compared  to healthycontrols (median: 35.1 pg/ml; range: 10.9-13676.6 pg/ml; P<0.01). Compared to the healthy control group, the decrease in serum interleukin-19 concentration was seen in all breast cancer stages. However the decrease was only significant for stage III (P=0.02). We found no significant association between serum interleukin-19 levels and stage, grade, lymph node involvement or other clinicopathological variables of the  disease. However, when  compared  to  the  healthy  control  group, we  found significantly decreased serum interleukin-19 levels in patients with involved lymph nodes (P<0.01) or tumor size greater than 2 cm (P=0.01).Conclusion: There were significantly decreased interleukin-19 levels in breastcancer patients compared to the healthy control group. We observed no associationbetween serum interleukin-19 levels and clinicopathological parameters in breastcancer patients.}, keywords = {}, url = {https://mejc.sums.ac.ir/article_42012.html}, eprint = {https://mejc.sums.ac.ir/article_42012_0cf75d292652adc145e4814261cb810c.pdf} }